This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Portfolio Pulse from Avi Kapoor
Several Wall Street analysts initiated coverage on key stocks with bullish ratings. Deutsche Bank rated GE Vernova (GEV) as Buy with a $354 target. Keybanc rated BKV Corporation (BKV) as Overweight with a $23 target. Jefferies rated Sarepta Therapeutics (SRPT) as Buy with a $165 target. Benchmark rated ESCO Technologies (ESE) as Buy with a $150 target. Truist Securities rated Guardian Pharmacy Services (GRDN) as Buy with a $22 target.
October 21, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keybanc initiated coverage on BKV Corporation with an Overweight rating and a price target of $23, suggesting a potential increase from the current price of $18.45.
The Overweight rating and price target above the current price indicate a likely positive impact on BKV's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Benchmark initiated coverage on ESCO Technologies with a Buy rating and a price target of $150, suggesting a potential increase from the current price of $126.20.
The Buy rating and price target above the current price indicate a likely positive impact on ESE's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Deutsche Bank initiated coverage on GE Vernova with a Buy rating and a price target of $354, indicating a potential upside from the current price of $272.72.
The initiation of coverage with a Buy rating and a significant price target above the current price suggests a positive short-term impact on GEV's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Truist Securities initiated coverage on Guardian Pharmacy Services with a Buy rating and a price target of $22, indicating a potential upside from the current price of $17.68.
The Buy rating and price target above the current price suggest a positive short-term impact on GRDN's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Jefferies initiated coverage on Sarepta Therapeutics with a Buy rating and a price target of $165, indicating a potential upside from the current price of $127.08.
The Buy rating and price target significantly above the current price suggest a positive short-term impact on SRPT's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100